FCGR2A and neoplasm: In addition, in patients with malignancy the FcγR polymorphism causes an increased response to antibody affected tumor cells as it was shown in leukemia, breast cancer (trastuzumab), and colon carcinoma (cetuximab) (Tamura et al. 2011; Weng and Levy 2003).